Published in Drug Week, April 29th, 2005
The researchers said their findings suggest drugs or compounds that activate the protective protein, called ataxin-3, might be a possible therapy for neurodegenerative diseases that are caused by proteins whose sequences are abnormally long due to excessive repetition of the amino acid glutamine.
The research team, led by Nancy M. Bonini, a Howard Hughes Medical Institute investigator at the University of Pennsylvania, published its findings in the April 1, 2005, issue...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.